Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 2/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.40 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | CHAT | P28329 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25764879 | 0.85 | KCNA3 (0.52) | KCNA3GRIK1GRIK2CACNA1BCYP1A2 | |
| SCHEMBL25759188 | 0.83 | GRIK1 (0.42) | KCNA3GRIK1GRIK2CACNA1BRELA | |
| SCHEMBL28812386 | 0.79 | CYP1A2 (0.50) | KCNA3GRIK1GRIK2CACNA1BRELA | |
| SCHEMBL25765199 | 0.79 | CYP1A2 (0.50) | KCNA3GRIK1GRIK2CACNA1BRELA | |
| SCHEMBL24019968 | 0.77 | CACNA1B (0.44) | KCNA3GRIK1GRIK2CACNA1BCYP1A2 | |
| SCHEMBL27713542 | 0.76 | CACNA1B (0.48) | GRIK1GRIK2CACNA1BRELACYP1A2 | |
| SCHEMBL9997659 | 0.75 | CYP1A2 (0.53) | GRIK1GRIK2CACNA1BRELACYP1A2 | |
| SCHEMBL9997657 | 0.75 | CYP1A2 (0.53) | GRIK1GRIK2CACNA1BRELACYP1A2 | |
| SCHEMBL28462959 | 0.75 | CYP1A2 (0.56) | GRIK1GRIK2CACNA1BCYP1A2CYP2C9 | |
| SCHEMBL24112747 | 0.75 | CYP1A2 (0.49) | GRIK1GRIK2CACNA1BRELACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | KCNA3 3755/4885GRIK1 4299/4885GRIK2 4003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.